Pembrolizumab vs Potassium Citrate Anhydrous
Pembrolizumab vs Potassium Citrate Anhydrous: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Potassium Citrate Anhydrous.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab β 26 days.
Chemical Properties
Type: Pembrolizumab β Antibody; Potassium Citrate Anhydrous β Small molecule.